10900 WILSHIRE BLVD, LOS ANGELES, CA
Increases Full Year 2025 Net Sales Outlook to 25% to 30% Year-Over-Year Growth
Financial Results, Reg. FD
News, Material Contracts
Reports First Quarter 2025 Financial Results and Increases Outlook
Annual Report to Security Holders
Evolves into Niagen Bioscience, Marking a New Era of Uncovering the Potential of NAD+ with Precision Science
Changes in Board, Management or Compensation
Q2
Q1
FY 2024
Q3
FY 2023
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(3)
Prospectus filed pursuant to Rule 424(b)(5)
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Additional Proxy Materials
Definitive Proxy Statement
PRE 14A
Statement of Changes in Beneficial Ownership
Correspondence
Submission Upload
Confidential Treatment Order